Search

Displaying results 2861 - 2870 of 8412 in total
  1. Drug

    Pleospora betae

    go.drugbank.com/drugs/DB10936
    Approved

    Pleospora betae is a fungus which can provoke allergic reactions. Pleospora betae extract is used in allergenic testing.

  2. Drug

    Trichophyton tonsurans

    go.drugbank.com/drugs/DB10970
    Approved

    Trichophyton tonsurans is a fungus which can provoke allergic reactions. Trichophyton tonsurans extract is used in allergenic testing.

  3. Drug

    Trichophyton verrucosum

    go.drugbank.com/drugs/DB11295
    Approved

    Trichophyton verrucosum is a fungus which can provoke allergic reactions. Trichophyton verrucosum extract is used in allergenic testing.

  4. Drug

    Enlonstobart

    go.drugbank.com/drugs/DB21890
    Investigational

    [A274486] It targets the programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.

  5. Drug

    Motixafortide

    go.drugbank.com/drugs/DB14939
    ApprovedInvestigational

    is commonly employed in the context of hematologic cancers - high-dose chemotherapy regimens destroy cancerous blood cells, which are then replaced via infusion of the patient's own stem cells (i.e. an … [L48136] Similar in mechanism to the previously approved [plerixafor], motixafortide is an inhibitor of C-X-C Motif Chemokine Receptor 4 (CXCR4), a protein that helps to anchor stem cells to bone marrow

  6. Drug

    Ivosidenib

    go.drugbank.com/drugs/DB14568
    ApprovedInvestigational

    IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  7. Drug

    Ponatinib

    go.drugbank.com/drugs/DB08901
    ApprovedInvestigational

    Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  8. Drug

    Fenfluramine

    go.drugbank.com/drugs/DB00574
    ApprovedIllicitInvestigationalWithdrawn

    [A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal … [A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSynonyms: DL-Fenfluramine
  9. Drug

    Clioquinol

    go.drugbank.com/drugs/DB04815
    ApprovedVet approvedWithdrawn

    Clioquinol was withdrawn in 1983 due to neurotoxicity.

    Mixtures: CORTINOL D
  10. Drug

    Oxazepam

    go.drugbank.com/drugs/DB00842
    Approved

    Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. … [A203516] It is an active metabolite of both [diazepam] and [temazepam][A39486] and undergoes very little biotransformation following absorption, making it unlikely to participate in pharmacokinetic interactions